Privia Health Group’s (PRVA) Market Outperform Rating Reaffirmed at JMP Securities

by · The Cerbat Gem

Privia Health Group (NASDAQ:PRVA – Get Free Report)‘s stock had its “market outperform” rating restated by equities researchers at JMP Securities in a research note issued to investors on Monday,Benzinga reports. They currently have a $29.00 price objective on the stock. JMP Securities’ target price would indicate a potential upside of 24.33% from the company’s previous close.

PRVA has been the topic of a number of other reports. Stephens reaffirmed an “overweight” rating and issued a $26.00 target price on shares of Privia Health Group in a report on Thursday, January 2nd. Canaccord Genuity Group boosted their price target on Privia Health Group from $29.00 to $30.00 and gave the company a “buy” rating in a research report on Friday, February 28th. Barclays increased their price objective on Privia Health Group from $21.00 to $23.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 10th. Piper Sandler raised their target price on shares of Privia Health Group from $25.00 to $40.00 and gave the stock an “overweight” rating in a research note on Friday, February 28th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $30.00 price objective on shares of Privia Health Group in a research report on Thursday, April 10th. One equities research analyst has rated the stock with a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $27.14.

View Our Latest Research Report on PRVA

Privia Health Group Trading Up 0.7 %

PRVA stock traded up $0.16 during trading on Monday, hitting $23.33. 80,351 shares of the company’s stock were exchanged, compared to its average volume of 767,476. Privia Health Group has a 52-week low of $15.92 and a 52-week high of $26.04. The stock has a market capitalization of $2.83 billion, a price-to-earnings ratio of 233.26, a PEG ratio of 3.47 and a beta of 0.88. The business has a 50-day moving average price of $23.64 and a two-hundred day moving average price of $21.94.

Insider Activity

In other news, CFO David Mountcastle sold 5,630 shares of the company’s stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $22.38, for a total transaction of $125,999.40. Following the completion of the transaction, the chief financial officer now owns 179,676 shares of the company’s stock, valued at $4,021,148.88. This represents a 3.04 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 10.70% of the company’s stock.

Hedge Funds Weigh In On Privia Health Group

Several institutional investors and hedge funds have recently bought and sold shares of PRVA. Rhumbline Advisers boosted its holdings in Privia Health Group by 1.3% in the fourth quarter. Rhumbline Advisers now owns 287,200 shares of the company’s stock valued at $5,615,000 after acquiring an additional 3,658 shares during the last quarter. Nordea Investment Management AB lifted its stake in shares of Privia Health Group by 33.1% in the 4th quarter. Nordea Investment Management AB now owns 349,773 shares of the company’s stock valued at $6,953,000 after purchasing an additional 86,910 shares in the last quarter. Franklin Resources Inc. grew its holdings in shares of Privia Health Group by 2.2% during the 3rd quarter. Franklin Resources Inc. now owns 1,300,240 shares of the company’s stock worth $23,092,000 after purchasing an additional 28,480 shares during the period. Barclays PLC raised its holdings in Privia Health Group by 240.3% in the third quarter. Barclays PLC now owns 224,018 shares of the company’s stock valued at $4,079,000 after buying an additional 158,188 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in Privia Health Group by 8.4% during the third quarter. JPMorgan Chase & Co. now owns 188,384 shares of the company’s stock valued at $3,430,000 after buying an additional 14,641 shares in the last quarter. Institutional investors and hedge funds own 94.48% of the company’s stock.

About Privia Health Group

(Get Free Report)

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.

Featured Stories